Latest Media News

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

RMA Global Limited has reported its first full year of positive operating cash flow alongside accelerating revenue growth in both the US and ANZ markets, driven by strategic product launches and expanded brokerage partnerships.

Dome Gold Mines reports delays in its Sigatoka desilting project due to local activist opposition, while progressing its feasibility study and securing key license renewals in Fiji.

Gladiator Resources reported promising uranium and rare metal findings at its Tanzanian projects while initiating legal action over alleged defamation, all against a backdrop of cautious cash management.

Aspermont Limited reports a 7% revenue increase driven by subscription growth and a landmark contract with a top global mining company, while preparing to launch new data products.

Sequoia Financial Group has responded to an ASX price query, denying any undisclosed material information behind recent trading fluctuations and reaffirming compliance with listing rules amid ongoing ASIC investigations.

WhiteHawk Limited reported solid Q2 revenue growth with new US contracts and is advancing its Australian market entry, while managing cash flow challenges.

ASF Group Limited reported a stable cash position of $1.3 million as of June 2025, accepted a takeover offer for its stake in Rey Resources, and continued to develop its innovative technology and biotech investments.

Resolution Minerals Limited is set to pursue a dual-listing on the NASDAQ in Q4 2025, aiming to tap into deeper U.S. capital markets and enhance its profile among American investors. The move supports the development of its critical minerals Horse Heaven project in Idaho, aligning with U.S. national security interests.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Adveritas Limited reports a robust 62% increase in annualised recurring revenue to $10.47 million and a record doubling of full-year cash receipts, backed by a strategic $8.5 million institutional placement to accelerate growth in the US and new verticals.

Elsight Limited has responded to ASX concerns over a premature media report on its $60 million capital raise, denying any unauthorized disclosures and reaffirming its compliance with continuous disclosure rules.